Abstract: Face recognition systems that are commonly used in access control settings are vulnerable to presentation attacks, which pose a significant security risk. Therefore, it is crucial to develop ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...